The themes Agilent Technologies is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
As participações na receita são estimativas para nine months ended July 31, 2026, não números de um relatório oficial.
Infinity III liquid chromatography systems
Instruments that separate the substances in a liquid sample so a laboratory can identify and measure them.
8890B and 8860B gas chromatographs
Instruments that separate and measure substances that can be turned into gas, including chemicals in fuels and contaminants in food.
9500 triple-quadrupole inductively coupled plasma mass spectrometer
An instrument that measures very small amounts of metals and other elements, including in samples used in semiconductor manufacturing.
Altura liquid chromatography columns
Replaceable tubes that separate substances inside a chromatography system, including in testing of protein-based and nucleic-acid medicines.
Dako Omnis pathology systems
Automated instruments and related supplies used by clinical laboratories to stain and examine tissue samples for cancer diagnosis.
Oligonucleotide contract manufacturing
Manufacturing of short DNA- or RNA-like drug ingredients for pharmaceutical customers, from development through commercial production.
Demonstrações financeiras completas →
Agilent makes instruments that help laboratories identify and measure the chemicals, cells and other materials in samples. It also sells the supplies used with those instruments, maintains lab equipment, and provides software for collecting and managing test results. For drug companies, Agilent also makes ingredients used in some medicines and manufactures certain drug materials under contract.
Construído a partir dos próprios documentos de Agilent Technologies, Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
A · NYSE · Healthcare · Diagnostics and Research
US$ 176,91-0,5%fechamento 11 de nov.
Próximos resultados: 23 de novembro de 2026 · após o fecho
Números até 31 de julho de 2026, do 10-Q arquivado em 1 de setembro de 2026
Agilent sells laboratory supplies and maintenance services, plus scientific instruments, to pharmaceutical companies, hospitals, research labs and testing laboratories.
Projeção da empresa: receita de de US$ 7,5B a US$ 7,5B para Ano fiscal 2026 — alta de 7,9% em relação ao ano anterior
Grade B+
A faixa sob o preço mostra a nota em cada data, calculada só com os documentos já públicos naquele momento.
Mostrando 2 de 40 trimestres do histórico de notas de Agilent Technologies, Inc.. Os outros 38 vão até dezembro de 2016.